Welcome to our dedicated page for Electrocore news (Ticker: ECOR), a resource for investors and traders seeking the latest updates and insights on Electrocore stock.
electroCore, Inc. (Nasdaq: ECOR) is a commercial-stage bioelectronic medicine and wellness company that regularly issues news on its non-invasive neuromodulation technologies, prescription therapies, and wellness and performance devices. This news feed aggregates company press releases, clinical study announcements, reimbursement developments, corporate updates, and other disclosures directly related to electroCore.
Readers can follow updates on electroCore’s prescription products, including gammaCore non-invasive vagus nerve stimulation (nVNS) and the Quell neurostimulator for chronic pain syndromes, as well as its handheld Truvaga and TAC-STIM devices for general wellness and human performance. News items have covered peer-reviewed studies on gammaCore in persistent post-concussion symptoms, controlled trials of TAC-STIM in active-duty Air Force trainees, and recognition of Truvaga Plus in consumer-focused awards.
The ECOR news stream also includes financial and corporate information such as quarterly results, revenue trends, private placements, participation in investor conferences, and changes to the board of directors and executive team. Regulatory and market access milestones, like reimbursement decisions for gammaCore Sapphire in Belgium, appear alongside product and clinical updates.
Investors, clinicians, and individuals interested in bioelectronic medicine can use this page to review electroCore’s historical and recent announcements in one place. For deeper analysis of any item, users can combine these news releases with the company’s SEC filings and other official documents accessible through related sections of the platform.
On August 2, 2021, electroCore announced its participation in the Canaccord Genuity Growth Conference, set for August 10-12, 2021. The company's management will present on August 12 at 8:30 am EDT. This conference offers a platform for virtual one-on-one meetings with investors. Following the event, a recording of the presentation will be accessible on the investor section of the company's website. electroCore specializes in bioelectronic medicine, focusing on non-invasive vagus nerve stimulation therapies for neurological conditions, including migraine and cluster headaches.
electroCore (Nasdaq: ECOR) announced the issuance of U.S. Patent No. 11,065,444 by the USPTO, covering a mobile phone method for trigeminal nerve stimulation to treat disorders like migraines. This patent details devices enabling self-treatment through non-invasive electrical stimulation. The handheld device targets nerves in the head to alleviate conditions, enhancing access to treatment. This patent expands electroCore's non-invasive pain management program, reinforcing its commitment to improving patient outcomes.
electroCore, Inc. (NASDAQ: ECOR) will report its financial results for the second quarter ending June 30, 2021, on August 5, 2021, after market close. A conference call and webcast for discussion will take place at 4:30 PM ET on the same day. electroCore focuses on bioelectronic medicine, utilizing a non-invasive vagus nerve stimulation therapy platform aimed at treating conditions like migraines and cluster headaches. The company emphasizes its commitment to enhancing patient outcomes through this innovative treatment approach.
electroCore, Inc. (NASDAQ: ECOR) announced that its cofounder and Chief Medical Officer, Dr. Peter Staats, will receive a Lifetime Achievement Award at the American Society of Pain and Neuroscience Annual Conference on July 24th, 2021. This award recognizes Dr. Staats' significant contributions to pain medicine, including over 450 published works. He has held leadership roles in various medical societies and is currently the President Elect of the World Institute of Pain. electroCore focuses on non-invasive vagus nerve stimulation therapies for migraine and cluster headache treatment.
electroCore, Inc. (ECOR) expects approximately $1.3 million in revenue for Q2 2021, a 5% increase from Q1 2021 and a 69% growth year-over-year. The company reported a net cash usage of about $3.2 million for operations in the same period. As of June 30, 2021, cash and equivalents totaled approximately $23.7 million, which does not include $18.8 million raised in a recent offering. The company emphasizes ongoing operations and international expansion efforts.
electroCore, Inc. (Nasdaq: ECOR) will be presenting at the Ladenburg Thalmann 2021 Virtual Healthcare Conference on July 14, 2021, at 3:30 PM. CEO Dan Goldberger will provide a comprehensive overview of the company and engage in one-on-one meetings. Interested parties can access the presentation through the provided webcast link.
Following the event, a replay will be available in the Investor section of electroCore's website. The company specializes in non-invasive vagus nerve stimulation therapies aimed at treating cluster headaches and migraines.
electroCore, Inc. (NASDAQ: ECOR) announced a public offering of 18 million shares at $1.00 each, raising approximately $18 million before expenses. The offering is expected to close around July 2, 2021. Underwriters have a 45-day option for an additional 2.7 million shares. Proceeds will support sales, marketing, working capital, and potential business expansions, although no specific acquisitions are currently planned. The offering is made under an effective shelf registration statement with the SEC.
electroCore, Inc. (NASDAQ: ECOR) announced a public offering of its common stock. The offering, which is subject to market conditions, aims to raise funds for sales, marketing, working capital, and potential acquisitions. The company will grant underwriters a 45-day option to purchase an additional 15% of shares. Ladenburg Thalmann & Co. Inc. is the sole book-runner, with Paulson Investment Company as co-manager. The offering will utilize an effective shelf registration statement filed with the SEC, and a preliminary prospectus will be available soon.
On June 10, 2021, electroCore, Inc. (Nasdaq: ECOR) announced the publication of a peer-reviewed study in Communications Biology highlighting the positive effects of non-invasive vagus nerve stimulation (nVNS) on cognitive performance in sleep-deprived Air Force personnel. The trial found that nVNS improved throughput capacity by 10% compared to a sham treatment, with lasting effects. This research opens avenues for nVNS in both military and civilian settings, addressing fatigue-related cognitive impairments. The findings suggest potential market growth for gammaCore's applications.
electroCore, Inc. (Nasdaq: ECOR) has partnered with Kromax International Corporation as the exclusive distributor of its gammaCore Sapphire™ non-invasive vagus nerve stimulator in Taiwan and China. This three-year agreement aims to enhance healthcare quality in pain management, particularly for migraine sufferers. The partnership is contingent on regulatory approvals, with the timing of these clearances currently uncertain. Both companies aim to improve patient outcomes through innovative healthcare solutions.